Publication
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerTriple-Negative Breast Carcinomacivic_curation1.00
- drugOlaparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Loss-of-functioncivic_curation1.00
- variantBRCA2 Loss-of-functioncivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 34081848
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Loss-of-function2 | ||||||||
| Olaparib | Triple-Negative Breast CarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11216Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC | civic |
| 〃 | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11201Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC | civic |
| BRCA2 Loss-of-function2 | ||||||||
| Olaparib | Triple-Negative Breast CarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11217Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC | civic |
| 〃 | HER2 Negative Breast CancerUNRESOLVED | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID11202Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC | civic |
| BRCA2 Mutation1 | ||||||||
| Olaparib | HER2 Negative Breast CancerUNRESOLVED | Predictive | B | Supports Sensitivity Response | 4 | rejected | EID11425A phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)–negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathoge… (full text at CIViC) PMID 34081848 · Tutt et al., 2021 · Open in CIViC | civic |